Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Catalyst Biosciences, Inc. is not a good value stock. Catalyst Biosciences, Inc. is not very popular among insiders. Catalyst Biosciences, Inc. is a good stock to invest in, but there are better stocks to choose.
Log in to see more information.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the devel...
CBIO Fundamental Data by TradingView

News

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding
Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

PR Newswire Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President...\n more…

Catalyst Biosciences announces completion of combination with GNI Group
Catalyst Biosciences announces completion of combination with GNI Group

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Globe Newswire The combined company will operate as Gyre Therapeutics, Inc. with its common stock traded on Nasdaq under trading symbol GYRE effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023...\n more…

Catalyst Biosciences (NASDAQ:CBIO) Share Price Crosses Above Two Hundred Day Moving Average of $0.29
Catalyst Biosciences (NASDAQ:CBIO) Share Price Crosses Above Two Hundred Day Moving Average of $0.29

Zolmax Catalyst Biosciences, Inc. (NASDAQ:CBIO Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.29 and...\n more…

CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO

Business Wire Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the merger of Catalyst Biosciences, Inc. (NasdaqCM: CBIO) and GNI Group Ltd. KSF is seeking to determine whether the transaction and the process that led to it...\n more…

Reviewing Catalyst Biosciences (NASDAQ:CBIO) and Apexigen (NASDAQ:APGN)
Reviewing Catalyst Biosciences (NASDAQ:CBIO) and Apexigen (NASDAQ:APGN)

Zolmax Catalyst Biosciences (NASDAQ:CBIO Free Report) and Apexigen (NASDAQ:APGN Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership...\n more…